Two Labs Joins GS1 Healthcare US Initiative
Two Labs Joins GS1 Healthcare US Initiative Two Labs is a new member of the GS1 Healthcare US Initiative and will be joining the Rx Supply Chain Security Workgroup (RxSSC) in 2020.The GS1 Healthcare US Initiative includes over [...]
Pricing and Market Access Considerations for Cell and Gene
Pricing and Market Access Considerations for Cell and Gene In the past two years, four cell and gene therapies have entered the U.S. market at unprecedented prices. Most recently, Zolgensma launched at a price of $2.1 [...]
What is Compendia’s Impact on Product Decision Making?
What is Compendia’s Impact on Product Decision Making? What is “The Compendia”? Most often, people describe the organizations that make up the Compendia as price books – and that’s understandable. After all, most of the submissions a manufacturer makes to [...]
An Overview of Cell and Gene Therapies
An Overview of Cell and Gene Therapies Since 2017, four new cell and gene therapies have become available in the U.S. with prices ranging from $373,000 to $2.1 million for a one-time administration. Gene [...]
Two Labs Acquires CEEK Enterprises
At Two Labs, our mission is to improve patients’ quality of life by delivering innovative trade and commercialization services to pharmaceutical manufacturers. This is why we’re pleased to announce that as of February 3, 2020, Two Labs has acquired [...]
Two Labs a Best Place to Work in Central Ohio
Two Labs is proud to be named as one of Columbus Business First’s 2019 Best Places to Work in Central Ohio. The Best Places to Work program, which is now in its 15th year, invites companies with at [...]